publication date: Sep. 29, 2017

In draft, USPSTF recommends screening with hrHPV without cytology

By Matthew Bin Han Ong

To detect high-grade precancerious cervical lesions and cervical cancer, women ages 30 to 65 may no longer need to rely on co-testing, and can choose to either screen for high-risk human papillomavirus types or undergo cervical cytology, according to a recent draft recommendation released by the U.S. Preventive Services Task Force.

The draft statement, which is open for public comment through Oct. 9, recommends screening for cervical cancer every three years with cervical cytology alone in women ages 21 to 29. For women ages 30 to 65, USPSTF recommends either screening every three years with cervical cytology alone, or every five years with hrHPV testing alone.

The task force said it found “convincing evidence” that screening with either test for women ages 30 to 65 substantially reduces cervical cancer incidence and mortality.

“This recommendation statement applies to asymptomatic women, regardless of their sexual history,” the task force wrote in the draft recommendation. “This recommendation statement does not apply to women who have been diagnosed with a high-grade precancerous cervical lesion or cervical cancer, women with in utero exposure to diethylstilbestrol, or women who have a compromised immune system.”

USPSTF found adequate evidence that screening women older than 65 who have had adequate prior screening and are not otherwise at high risk for cervical … Continue reading In draft, USPSTF recommends screening with hrHPV without cytology

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.